Asset Details
Do you wish to reserve the book?
Rising metastatic prostate cancer rates but narrowing racial gap
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rising metastatic prostate cancer rates but narrowing racial gap
Do you wish to request the book?
Rising metastatic prostate cancer rates but narrowing racial gap
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rising metastatic prostate cancer rates but narrowing racial gap
2025
Overview
Background
In recent years, there has been considerable interest in addressing racial disparities in prostate cancer (PCa) care including risk-adapted screening. This study examined trends in metastatic PCa incidence by race and placed them in context of changes in PSA screening recommendations.
Methods
We analyzed metastatic PCa incidence trends by race (using Surveillance Epidemiology and End Results data, 2005–2021) and PSA screening trends (using Behavioral Risk Factors Surveillance Survey data, 2012–2020). We fitted a generalized linear model with an interaction term for race and year of diagnosis and calculated annual incidence rate ratios (metastatic disease) and odds ratios (screening) for Non-Hispanic Black (NHB) vs. Non-Hispanic White (NHW) men.
Results
From 2005 to 2021, the age-adjusted metastatic PCa incidence (per 100,000) increased from 16.4 to 22.3 in NHB men, and from 6.2 to 10.8 in NHW men. While the incidence increased in both groups, the NHB vs. NHW incidence rate ratio declined from 2.6 (95%CI: 2.4, 2.9) in 2005 to 2.1 (95%CI:2.0,2.2) in 2021 (
p
< .0001), indicating a narrowing racial gap. From 2012 to 2020, PSA screening declined in both groups. NHB men initially had higher rates (OR:1.34, 95%CI: 1.21, 1.49,
p
< 0.0001) but experienced a steeper decline, resulting in no significant difference by 2020 (OR: 1.04, 95% CI: 0.91, 1.19,
p
= 0.59).
Conclusions
The racial gap in metastatic PCa narrowed over the study period, while overall incidence increased. Higher screening rates among Black men in the early 2010s may explain the narrowing gap. The subsequent more rapid decline among Black men raises concerns about resurgence of racial disparities in the coming years.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Behavioral Risk Factor Surveillance System (BRFSS)
/ Black or African American - statistics & numerical data
/ Healthcare Disparities - ethnology
/ Humans
/ Male
/ Medicine
/ Metastatic prostate cancer incidence
/ Prostate-Specific Antigen - blood
/ Prostatic Neoplasms - diagnosis
/ Prostatic Neoplasms - epidemiology
/ Prostatic Neoplasms - ethnology
/ Prostatic Neoplasms - pathology
/ Race
/ Surveillance Epidemiology and End Results Program (SEER)
